Stay updated on GM T-cell Therapy in AML/BPDCN Clinical Trial
Sign up to get notified when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.

Latest updates to the GM T-cell Therapy in AML/BPDCN Clinical Trial page
- ChecktodayChange DetectedThe record now presents details of a phase I CD123 CAR T-cell immunotherapy study, including its treatment plan, eligibility criteria, outcome measures, collaborators, and current recruitment status.SummaryDifference71%

- Check7 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedThe footer’s site revision changes from v3.7.0 to v3.7.1, while the 403 error page remains otherwise unchanged.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, with a minimal header/footer visible, indicating the content is currently inaccessible.SummaryDifference22%

- Check50 days agoChange DetectedA Publications section has been added to the study record, including the PubMed cited article for the phase I trial. It also notes that publications may be automatically filled from PubMed.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page’s revision metadata was updated to v3.6.6 and new dates (2026-08-26, 2026-08-24, 2026-08, 2027-07-14) were added. The previous revision (v3.6.5) and earlier dates were removed.SummaryDifference0.3%

Stay in the know with updates to GM T-cell Therapy in AML/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GM T-cell Therapy in AML/BPDCN Clinical Trial page.